Graftless Maxillary Sinus Augmentation With CGF Utilizing DIVA System

NCT ID: NCT02985645

Last Updated: 2016-12-08

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-12-31

Study Completion Date

2018-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is intended to evaluate the efficiency of graftless maxillary sinus augmentation with concentrated growth factor (CGF) utilizing "dynamic implant valve approach" (DIVA) system.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Crestal bone deficiency in the posterior maxilla may present a therapeutic challenge when dental implants are required. Sufficient bone volume is necessary for the long term survival of the implant .

The two most used surgical techniques are the crestal and the lateral window. The latter was first described by Tatum and subsequently, Boyene and James in 1980 . In the original technique, after fracturing the sinus floor, an implant was placed and submerged during the healing phase. The crestal osteotome technique is less invasive and was first described by Summers in 1994 . In this technique, a set of osteotomes is used to prepare the implant site, thereby allowing bone preservation.

Since the sinus augmentation was describes, bone grafts have been the mainstay of treatment. Variable bone grafts, such as autografts, allografts, xenografts, alloplasts, or combinations of different graft materials, have been used widely with similar results . Nonetheless, successful bone augmentation in the maxillary sinus, without bone grafting, have been reported in human and animal studies.

In 2011, Dong-Seok et al described sinus augmentation through a lateral window approach, using a fibrin rich block with concentrated growth factor (CGF). The researchers showed successful new bone formation in the sinus, with a success rate of 98% and no major complications .

Graftless Sinus augmentation relies on bioactive mediators that stimulate cell proliferation, matrix remodeling, and angiogenesis. CGF is one of the latest developments in this field, and is produced by processing blood samples with a special centrifuge device. It contains several mediators - platelet-derived growth factor (PDGF), transforming growth factor-b1 (TGF-b1) and b2 (TGF-b2), fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF), and insulin-like growth factor (IGF). Because CGF is a dense fibrin matrix, richer in growth factors than other preparations, it has proved to have a better regenerative capacity and versatility .

As for the application of CGF, the introduction of the "dynamic implant valve approach" (DIVA), a minimally invasive approach procedure, enables the use of a closed bone augmentation technique. The implant was designed with an internal sealing screw that might serve as drug delivery system via its channel.

In this study, a graftless maxillary sinus augmentation with CGF will be performed utilizing DIVA system, and the bone formation will be periodically measured using panoramic X-ray and cone beam computerized tomography (CBCT).

In addition, in vitro cumulative release of selected growth factors of the CGF will be analyzed. The total quantity of growth factors will be checked using ELISA kits.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Alveolar Bone Loss

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

CGF sinus augmentation DIVA Platelet-Rich Plasma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment

maxillary sinus augmentation with CGF

Group Type EXPERIMENTAL

maxillary sinus augmentation with CGF

Intervention Type PROCEDURE

Graftless maxillary sinus augmentation surgery with CGF application utilizing DIVA system

"dynamic implant valve approach" - DIVA system

Intervention Type DEVICE

The DIVA system will be used to apply the CGF to the maxillary sinus.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

maxillary sinus augmentation with CGF

Graftless maxillary sinus augmentation surgery with CGF application utilizing DIVA system

Intervention Type PROCEDURE

"dynamic implant valve approach" - DIVA system

The DIVA system will be used to apply the CGF to the maxillary sinus.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* No medical history of diseases involving bone metabolism
* Patients that are treated by a prostodontist
* Healthy oral cavity and sinuses, and good oral hygiene
* No bone pathology demonstrated by X-ray
* Residual sub-antral bone of at least 4mm as demonstrated by computerized tomography (CT)
* The patient does not participate in another clinical study
* The patient can read and understand the informed consent

Exclusion Criteria

* Medical history of a disease affecting bone metabolism (Diabetes Mellitus, heart disease, renal failure, osteoporosis)
* Medical treatment that can affect bone metabolism (such as Bisphosphonates)
* Patients treated with anticoagulants (such as Coumadin, Pradaxa)
* Personal history of chemotherapy or radiotherapy
* Patients with maxillary sinus pathology
* Patients lacking a prostodontic treatment plan
* Pregnant women
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Western Galilee Hospital-Nahariya

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

ruth angel dar

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Samer Srouji, Prof.

Role: STUDY_DIRECTOR

Western Galilee Medical Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Western Galilee Medical Center

Nahariya, , Israel

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Israel

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Ruth Angel-Dar, Dr.

Role: CONTACT

Phone: +972-4-9107076

Email: [email protected]

Samer Srouji, Prof.

Role: CONTACT

Phone: +972-4-9107270

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Sigal Shor

Role: primary

References

Explore related publications, articles, or registry entries linked to this study.

Del Fabbro M, Corbella S, Weinstein T, Ceresoli V, Taschieri S. Implant survival rates after osteotome-mediated maxillary sinus augmentation: a systematic review. Clin Implant Dent Relat Res. 2012 May;14 Suppl 1:e159-68. doi: 10.1111/j.1708-8208.2011.00399.x. Epub 2011 Nov 14.

Reference Type BACKGROUND
PMID: 22082056 (View on PubMed)

Tatum H Jr. Maxillary and sinus implant reconstructions. Dent Clin North Am. 1986 Apr;30(2):207-29.

Reference Type BACKGROUND
PMID: 3516738 (View on PubMed)

Summers RB. The osteotome technique: Part 3--Less invasive methods of elevating the sinus floor. Compendium. 1994 Jun;15(6):698, 700, 702-4 passim; quiz 710.

Reference Type BACKGROUND
PMID: 7994726 (View on PubMed)

Danesh-Sani SA, Loomer PM, Wallace SS. A comprehensive clinical review of maxillary sinus floor elevation: anatomy, techniques, biomaterials and complications. Br J Oral Maxillofac Surg. 2016 Sep;54(7):724-30. doi: 10.1016/j.bjoms.2016.05.008. Epub 2016 May 25.

Reference Type BACKGROUND
PMID: 27235382 (View on PubMed)

Falah M, Sohn DS, Srouji S. Graftless sinus augmentation with simultaneous dental implant placement: clinical results and biological perspectives. Int J Oral Maxillofac Surg. 2016 Sep;45(9):1147-53. doi: 10.1016/j.ijom.2016.05.006. Epub 2016 May 31.

Reference Type BACKGROUND
PMID: 27256011 (View on PubMed)

Sohn DS, Kim WS, An KM, Song KJ, Lee JM, Mun YS. Comparative histomorphometric analysis of maxillary sinus augmentation with and without bone grafting in rabbit. Implant Dent. 2010 Jun;19(3):259-70. doi: 10.1097/ID.0b013e3181df1406.

Reference Type BACKGROUND
PMID: 20523182 (View on PubMed)

Sohn DS, Heo JU, Kwak DH, Kim DE, Kim JM, Moon JW, Lee JH, Park IS. Bone regeneration in the maxillary sinus using an autologous fibrin-rich block with concentrated growth factors alone. Implant Dent. 2011 Oct;20(5):389-95. doi: 10.1097/ID.0b013e31822f7a70.

Reference Type BACKGROUND
PMID: 21881519 (View on PubMed)

Rodella LF, Favero G, Boninsegna R, Buffoli B, Labanca M, Scari G, Sacco L, Batani T, Rezzani R. Growth factors, CD34 positive cells, and fibrin network analysis in concentrated growth factors fraction. Microsc Res Tech. 2011 Aug;74(8):772-7. doi: 10.1002/jemt.20968.

Reference Type BACKGROUND
PMID: 21780251 (View on PubMed)

Nahlieli O. Dynamic implant valve approach for dental implant procedures. Chin J Dent Res. 2014;17(1):15-21.

Reference Type BACKGROUND
PMID: 25028685 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

0153-16-NHR

Identifier Type: -

Identifier Source: org_study_id